1. Home
  2. URGN vs STDN Comparison

URGN vs STDN Comparison

Compare URGN & STDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$43.39

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Standard Nuclear Inc. Class A Common Stock

STDN

Standard Nuclear Inc. Class A Common Stock

N/A

Current Price

$16.56

Market Cap

1.9B

ML Signal

N/A

Company Overview

Basic Information
Metric
URGN
STDN
Founded
2004
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
2016
2026

Fundamental Metrics

Financial Performance
Metric
URGN
STDN
Price
$43.39
$16.56
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$29.29
N/A
AVG Volume (30 Days)
985.0K
766.0K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,128,000.00
N/A
Revenue This Year
$129.09
N/A
Revenue Next Year
$70.96
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.86
$7.05
52 Week High
$50.81
$16.22

Technical Indicators

Market Signals
Indicator
URGN
STDN
Relative Strength Index (RSI) 45.28 71.11
Support Level $18.25 $11.50
Resistance Level $43.93 N/A
Average True Range (ATR) 1.82 1.37
MACD -0.90 0.40
Stochastic Oscillator 14.81 89.22

Price Performance

Historical Comparison
URGN
STDN

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

About STDN Standard Nuclear Inc. Class A Common Stock

Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.

Share on Social Networks: